• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International Journal of Cancer =: Journal International du Cancer >Longitudinal quality of life data can provide insights on the impact of adjuvant treatment for pancreatic cancer-Subset analysis of the ESPAC-1 data.
【24h】

Longitudinal quality of life data can provide insights on the impact of adjuvant treatment for pancreatic cancer-Subset analysis of the ESPAC-1 data.

机译：纵向生活质量数据可提供有关辅助治疗对胰腺癌影响的见解-ESPAC-1数据的子集分析。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The European Study Group for Pancreatic Cancer (ESPAC-1) study is the largest study of adjuvant treatment for pancreatic ductal adenocarcinoma to date and confirmed a survival advantage for adjuvant chemotherapy but not for chemoradiation. The importance of parallel evaluation of survival and quality of life (QoL) has been recognized as fundamental and the aim was to assess QoL and quality adjusted survival. A longitudinal QoL study on a subset of ESPAC-1 patients who prospectively completed the EORTC QLQ C-30 questionnaire during treatment and follow-up. An integrated quality-survival product method was used to adjust any treatment effect on survival by a function of measured QoL, calculated over a restricted 24-month-period (QALM-24). Three hundred and sixteen patients completed 1,201 questionnaires. There were no differences between treatment groups in dimension scores at baseline (randomization). For the chemotherapy group, the mean Quality Adjusted Life Months over 24 months (QALM-24) was 9.6 (95%CI: 8.7, 11.2) months compared with the mean QALM-24 of 8.6 (95% CI: 7.6, 10.5) months for the no chemotherapy group. For the chemoradiation group, the mean QALM-24 was 7.1 (95% CI: 6.0, 9.0) months compared with the mean QALM-24 of 8.1 (95% CI: 7.0, 10.0) months for the no chemoradiation group. The previously reported survival advantage supporting the use of adjuvant chemotherapy is maintained when adjusted using quality adjusted survival methodology. Chemotherapy provided on average an additional 1.0 quality-adjusted life months within a restricted 2-year time period from the time of resection.
机译：欧洲胰腺癌研究小组（ESPAC-1）的研究是迄今为止胰腺导管腺癌辅助治疗的最大研究，它证实了辅助化疗的生存优势而不是化学放疗的生存优势。并行评估生存和生活质量（QoL）的重要性已被认为是基本的，目的是评估生存质量和质量调整后的生存。对在治疗和随访期间预期完成EORTC QLQ C-30问卷的ESPAC-1患者亚组的纵向QoL研究。通过在限定的24个月内（QALM-24）计算得出的QoL，使用综合的质量生存产品方法来调整对生存的任何治疗效果。 316名患者完成了1,201份问卷。治疗组之间在基线时的维度得分没有差异（随机化）。对于化疗组，平均24个月的质量调整生命月（QALM-24）为9.6（95％CI：8.7，11.2）个月，而QALM-24的平均质量调整月为8.6（95％CI：7.6，​​10.5）个月对于无化疗组。对于化学放疗组，平均QALM-24为7.1（95％CI：6.0，9.0）个月，而对于非化学放疗组，平均QALM-24为8.1（95％CI：7.0,10.0）个月。使用质量调整后的生存方法进行调整时，可以维持先前报道的支持辅助化疗的生存优势。自切除之日起的两年内，化学疗法平均可提供额外的1.0个质量调整生命周期。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号